LILLY IN ZYPRESPACE: ZYPREXA EXCITES 30% MARKET JUMP IN 1996; GLAXO ZANTAC, ZOVIRAX PATENT EXPIRATIONS WILL TEST BULL's STRENGTH; BRISTOL WEATHERS CAPOTEN
Lilly's launch of the antipsychotic Zyprexa is impressing Wall Street and helping to convince investors that there is an active life for the company as it moves into Prozac maturity
You may also be interested in...
Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.
In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.
Evotec is building a gene therapy R&D center manned by ex-Takeda scientists and has already landed a multi-year drug discovery pact for it with their former Japanese employer.